Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.

@article{Nissen2007EffectOR,
  title={Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.},
  author={Steven E. Nissen and Kathy E. Wolski},
  journal={The New England journal of medicine},
  year={2007},
  volume={356 24},
  pages={
          2457-71
        }
}
BACKGROUND Rosiglitazone is widely used to treat patients with type 2 diabetes mellitus, but its effect on cardiovascular morbidity and mortality has not been determined. METHODS We conducted searches of the published literature, the Web site of the Food and Drug Administration, and a clinical-trials registry maintained by the drug manufacturer (GlaxoSmithKline). Criteria for inclusion in our meta-analysis included a study duration of more than 24 weeks, the use of a randomized control group… 

Tables from this paper

Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality.

The totality of randomized clinical trials continue to demonstrate increased risk for MI although not for CV or all-cause mortality, and the current findings suggest an unfavorable benefit to risk ratio for rosiglitazone.

Was there really any evidence that rosiglitazone increased the risk of myocardial infarction or death from cardiovascular causes?

Rosiglitazone does not seem to have any significant increase in the risk of myocardial infarction or of death from cardiovascular causes associated with its use and regulatory authorities should revisit this issue of the appropriate measure for reporting of adverse events with low baseline risks.

Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis.

The interim findings from this ongoing study were inconclusive regarding the effect of rosiglitazone on the overall risk of hospitalization or death from cardiovascular causes.

Uncertain Effects of Rosiglitazone on the Risk for Myocardial Infarction and Cardiovascular Death

A meta-analysis of 42 clinical trials involving 27847 patients concluded that treatment with rosiglitazone, a widely prescribed, peroxisome proliferator-activated receptor- agonist, was associated with an approximately 43% greater risk for myocardial infarction and an approximately 64% greaterrisk for cardiovascular death than placebo or other antidiabetic regimens.

Long-term risk of rosiglitazone on cardiovascular events - a systematic review and meta-analysis.

Among patients with T2DM, rosiglitazone is associated with a significantly increased risk of heart failure, with little increasedrisk of myocardial infarction, without a significantlyIncreased risk of stroke, cardiovascular mortality, and all-cause mortality compared with placebo or active controls.

Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis.

Among patients with impaired glucose tolerance or type 2 diabetes, rosiglitazone use for at least 12 months is associated with a significantly increased risk of myocardial infarction and heart failure, without a significantlyIncreased risk of cardiovascular mortality.

Does rosiglitazone increase cardiovascular outcomes?

  • S. Doggrell
  • Medicine
    Expert opinion on pharmacotherapy
  • 2007
It seems that rosiglitazone may have a small harmful effect on cardiovascular outcomes, but this should not be cause for alarm and for a larger trial to determine the unequivocal effect.

Rosiglitazone and cardiovascular disease: a cardiologist's perspective

  • N. Marx
  • Medicine
    Diabetes & vascular disease research
  • 2007
The authors concluded that their interim findings were inconclusive regarding the effect of rosiglitazone on the overall risk of hospitalisation or death from cardiovascular causes, with no evidence of any increase in death from either cardiovascular causes or all causes.
...

References

SHOWING 1-10 OF 38 REFERENCES

A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes.

Investigation of the cardiac safety and antihyperglycemic effect of rosiglitazone in patients with type 2 diabetes found decreases in ambulatory diastolic blood pressure with RSG were superior to those with GLB.

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.

The potential risks and benefits, the profile of adverse events, and the costs of these three drugs should all be considered to help inform the choice of pharmacotherapy for patients with type 2 diabetes.

Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD): study design and protocol

The RECORD study should provide robust data on the extent to which rosiglitazone, in combination with metformin or sulphonylurea therapy, affects CV outcomes and progression of diabetes in the long term.

Rosiglitazone monotherapy is effective in patients with type 2 diabetes.

In the short-term, rosiglitazone is an insulin sensitizer that is effective and safe as monotherapy in patients with type 2 diabetes who are inadequately controlled by lifestyle interventions.

A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes.

The addition of RSG to insulin treatment results in significant improvement in glycemic control and is generally well tolerated.

Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003.

Beneficial effects of TZDs on glycemia and cardiovascular risk factors have made them attractive agents in patients with type 2 diabetes who are at high risk for CVD, there is a growing recognition, however, that edema can occur in patients treated with either drug.

Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial.

The data suggest that combination treatment with once-daily metformin-rosiglitazone improves glycemic control, insulin sensitivity, and beta-cell function more effectively than treatment with met formin alone.

An International Study of the Effects of Rosiglitazone plus Sulphonylurea in Patients with Type 2 Diabetes

This study shows that adding rosiglitazone to existing SU treatment improves glycaemic control and is well-tolerated in patients with type 2 diabetes from a wide range of non-Western countries.